EU CBD Novel Food Regulation: Compliance Requirements and Market Impact

Executive Summary

The European Union's Novel Food Regulation has created a complex legal framework that treats CBD-containing products as novel foods requiring pre-market authorization, fundamentally reshaping the continent's cannabidiol industry since 2019. Under Regulation (EU) 2015/2283, any food not consumed to a significant degree within the EU before May 15, 1997 must undergo safety assessment before being placed on the market. The European Commission's 2019 determination that CBD extracts and isolates constitute novel foods triggered a cascade of regulatory actions across member states, with France becoming one of the most restrictive jurisdictions by implementing a comprehensive ban on CBD edibles in May 2026. This regulatory framework affects an estimated €1.3 billion European CBD market, impacts thousands of hemp operators, and creates significant uncertainty for consumers seeking cannabidiol products for wellness purposes. The regulation requires manufacturers to submit extensive safety dossiers, conduct toxicological studies, and obtain explicit authorization before marketing CBD food products—a process that has cost individual applicants upward of €500,000 and taken multiple years without a single authorization granted as of mid-2026.

Why This Matters

The EU Novel Food framework for CBD affects every stakeholder in the European hemp supply chain, from farmers to retailers to millions of consumers. The European Industrial Hemp Association estimates that approximately 400,000 hectares of industrial hemp were cultivated across the EU in 2025, with CBD extraction representing a critical revenue stream for agricultural producers. The novel food designation creates a fundamental market access barrier that has forced hundreds of CBD businesses to cease operations or pivot to cosmetic and topical products not intended for ingestion. For consumers, the regulatory uncertainty means reduced access to CBD products that many use for sleep support, stress management, and general wellness. Survey data from the European Cannabis Industry Council indicates that approximately 8 million Europeans regularly consumed CBD products as of 2024, with that number declining as enforcement actions intensified. The France ban on CBD edibles alone affects an estimated 1.2 million French consumers who previously purchased CBD-infused foods, beverages, and dietary supplements. Investment capital has largely fled the European CBD food sector due to regulatory risk. Venture funding for EU-based CBD edible companies dropped 73% between 2022 and 2025 according to cannabis industry analysts, with capital redirecting toward North American markets or EU cosmetic applications. Multi-state operators with European ambitions have delayed or abandoned expansion plans, while established European hemp processors face existential threats to their business models. The regulatory framework also carries significant federalism implications, as individual EU member states interpret and enforce the novel food rules differently. This patchwork creates competitive distortions within the single market, with some jurisdictions tolerating CBD edibles while others, like France, implement outright prohibitions. The European Court of Justice has weighed in on related CBD questions, but fundamental tensions between EU-level food safety law and national enforcement discretion remain unresolved.

Background and History

The EU Novel Food Regulation framework emerged from decades of European food safety harmonization efforts, with CBD becoming entangled in this system through a 2019 administrative determination.

Origins of Novel Food Regulation (1997-2015)

The concept of "novel foods" entered European law with Regulation (EC) No 258/97, adopted in January 1997. This regulation established that foods and food ingredients not used for human consumption to a significant degree within the European Union before May 15, 1997 required safety assessment before market placement. The cutoff date of May 15, 1997 became critical for CBD, as it predated the modern cannabidiol extraction industry. The original regulation aimed to address emerging food technologies including genetically modified organisms, irradiated foods, and ingredients derived from new sources. Hemp and cannabis were not primary considerations during the 1990s drafting process, as the European hemp industry focused primarily on fiber and seed applications rather than cannabinoid extraction.

Modernization and Regulation (EU) 2015/2283

The European Parliament and Council adopted Regulation (EU) 2015/2283 on November 25, 2015, which entered into application on January 1, 2018. This modernized framework streamlined authorization procedures, centralized the application process through the European Food Safety Authority, and clarified the definition of novel foods. Article 3 of Regulation (EU) 2015/2283 defines novel food as food that was not used for human consumption to a significant degree within the Union before May 15, 1997, encompassing ten specific categories including food from plants or parts thereof. The regulation established a centralized authorization procedure requiring applicants to submit comprehensive safety dossiers to EFSA. Authorization decisions require approval by the European Commission and member states through the Standing Committee on Plants, Animals, Food and Feed. The process typically requires 18-36 months even for straightforward applications, with complex novel food dossiers taking substantially longer.

The 2019 CBD Determination

On January 20, 2019, the European Commission's Novel Food Catalogue was updated to classify "Cannabinoids" as novel foods. The entry specifically stated: "Extracts of Cannabis sativa L. and derived products containing cannabinoids are considered novel foods as a history of consumption has not been demonstrated." This administrative determination did not result from new legislation or formal rulemaking, but rather from an internal assessment by Commission officials regarding the consumption history of CBD extracts. The 2019 classification immediately rendered thousands of existing CBD products technically non-compliant with EU food law. Companies selling CBD oils, edibles, beverages, and dietary supplements faced the prospect that their products required novel food authorization—a process none had completed because the requirement was newly articulated. The European Industrial Hemp Association and other industry groups immediately challenged the determination, arguing that hemp extracts had been consumed in various forms for centuries and that CBD naturally occurring in hemp should not require novel food authorization. The Commission maintained that while hemp seeds and hemp seed oil had established consumption history, isolated or synthetic cannabidiol extracts did not.

Narcotic Classification Controversy (2020-2021)

In June 2020, the European Commission took the additional position that CBD should be considered a narcotic under the 1961 UN Single Convention on Narcotic Drugs, further complicating its regulatory status. This determination suggested that CBD products might be entirely prohibited rather than merely subject to novel food requirements. The European Court of Justice addressed this issue in its landmark judgment in Case C-663/18 (BS and CA) on November 19, 2020. The Court ruled that CBD extracted from the Cannabis sativa plant in its entirety does not constitute a drug under the 1961 Convention, as only extracts and tinctures of cannabis—not the plant's other parts such as fibers and seeds—fall within the Convention's scope. The ECJ further held that member states cannot prohibit the marketing of CBD lawfully produced in another member state unless it poses a genuine risk to public health. This ruling clarified that CBD itself is not a narcotic, but it did not resolve the novel food question. The Commission subsequently removed references to CBD as a narcotic but maintained the novel food classification.

Application Submissions and EFSA Review (2019-2026)

Following the 2019 determination, multiple companies submitted novel food applications for CBD. The European Food Safety Authority received at least 19 formal applications for CBD-containing products between 2019 and 2025. These applications covered CBD isolates, full-spectrum hemp extracts, and CBD-infused food products at various concentration levels. As of May 2026, EFSA has not issued a positive safety opinion for any CBD novel food application. The assessment process has been prolonged by data gaps regarding genotoxicity, reproductive toxicity, and appropriate daily intake levels. EFSA's Novel Foods Panel has repeatedly requested additional studies from applicants, particularly concerning potential genotoxicity signals observed in some in vitro assays. In March 2022, EFSA published a statement noting that several CBD applications were on hold pending clarification of genotoxicity concerns. The agency indicated that applicants needed to provide additional data demonstrating that CBD does not pose genotoxicity risks at proposed use levels. This requirement added an estimated €200,000-400,000 in additional testing costs per application and extended timelines by 12-24 months.

Member State Enforcement Divergence (2020-2026)

While the novel food determination applied EU-wide, enforcement varied dramatically across member states. Germany initially adopted a relatively permissive approach, with many CBD products remaining on the market pending novel food authorizations. The Netherlands similarly tolerated CBD sales with relatively limited enforcement actions through 2024. France took a more restrictive stance from the outset. French authorities conducted raids on CBD shops, seized products, and prosecuted retailers for selling unauthorized novel foods. The Interministerial Mission for Combating Drugs and Addictive Behaviors (MILDECA) maintained that CBD products posed public health risks and should be removed from the market. Italy experienced significant enforcement oscillation, with some regions tolerating CBD sales while others conducted aggressive enforcement campaigns. Spain saw similar regional variation, with Catalonia and Madrid adopting different practical approaches despite operating under the same EU framework.

France's 2026 Comprehensive Ban

On May 19, 2026, France implemented a comprehensive prohibition on CBD edibles under the novel food framework. The Direction Générale de la Concurrence, de la Consommation et de la Répression des Fraudes (DGCCRF) issued guidance stating that all CBD-containing foods, beverages, and dietary supplements constitute unauthorized novel foods and must be removed from the French market immediately. The guidance provided no grace period and mandated immediate compliance. The French ban affects an estimated 1,500 retail locations and 300 CBD brands operating in France. Trade associations estimate that the prohibition eliminates approximately €180 million in annual retail sales and threatens 4,000 jobs in the French CBD sector. The ban does not affect CBD cosmetics or topical products not intended for ingestion, creating a bifurcated market where the same molecule faces different regulatory treatment based on application method.

Key Players

European Commission

The European Commission's Directorate-General for Health and Food Safety (DG SANTE) administers the novel food framework and maintains the Novel Food Catalogue. The Commission made the initial 2019 determination classifying CBD extracts as novel foods and continues to coordinate member state enforcement approaches. The Commission has not publicly indicated any timeline for resolving the CBD novel food question or streamlining the authorization process.

European Food Safety Authority (EFSA)

EFSA's Panel on Nutrition, Novel Foods and Food Allergens (NDA Panel) conducts scientific risk assessments of novel food applications. The agency has received multiple CBD applications but has not issued positive opinions due to outstanding safety questions. EFSA operates independently from political pressure but faces criticism from industry stakeholders who argue the agency applies disproportionately stringent standards to CBD compared to other botanical extracts.

European Industrial Hemp Association (EIHA)

The EIHA represents hemp farmers, processors, and manufacturers across Europe. The association has consistently challenged the novel food classification for CBD, arguing that hemp extracts have documented consumption history predating 1997. EIHA commissioned legal opinions and historical research attempting to demonstrate that CBD-containing hemp preparations were consumed in various EU member states before the May 1997 cutoff. The association advocates for a consumption history exemption or streamlined authorization pathway for hemp-derived CBD.

Member State Competent Authorities

Each EU member state designates competent authorities responsible for enforcing food safety law within their territory. In France, the DGCCRF serves this function and has taken the most aggressive enforcement stance. Germany's Federal Office of Consumer Protection and Food Safety (BVL) has adopted a more measured approach, focusing enforcement on products making therapeutic claims rather than all CBD edibles. The Netherlands Food and Consumer Product Safety Authority (NVWA) has similarly exercised enforcement discretion, prioritizing products with elevated THC levels or misleading labeling.

CBD Industry Operators

Hundreds of European companies have built business models around CBD extraction, manufacturing, and retail. Major players include Endoca (Denmark), Harmony (UK), Cibdol (Switzerland), and Hempoint (Czech Republic). These companies have invested millions in cultivation infrastructure, extraction equipment, and product development based on the assumption that CBD would achieve regulatory clarity. The prolonged novel food uncertainty has forced many operators to pivot toward cosmetic applications, exit the European market entirely, or operate in legal gray zones.

Consumer Advocacy Organizations

Groups such as the European Cannabis Industry Council and Prohibition Partners advocate for science-based CBD regulation that balances consumer access with safety oversight. These organizations argue that the novel food framework, designed for GMOs and synthetic ingredients, is poorly suited to botanical extracts with traditional use histories. They point to CBD's legal status in the United States, Canada, and Switzerland as evidence that appropriate regulatory frameworks can provide market access while ensuring consumer protection.

Legal and Regulatory Framework

The EU Novel Food Regulation for CBD operates through a complex interaction of EU-level food safety law, member state enforcement authority, and international drug control treaties.

Primary Legal Instruments

Regulation (EU) 2015/2283 serves as the foundational legal text. Article 3(2)(a)(v) defines novel food to include "food consisting of, isolated from or produced from plants or their parts" where the food does not have a history of safe use as food within the Union before May 15, 1997. Article 6 establishes that novel foods may only be placed on the EU market after inclusion in the Union list of authorized novel foods. Article 10 of Regulation (EU) 2015/2283 sets forth application requirements, mandating that applicants submit comprehensive dossiers including proposed uses and use levels, detailed composition data, production process descriptions, and safety assessments addressing toxicology, allergenicity, and nutritional impact. The regulation requires applicants to demonstrate that the novel food, under proposed conditions of use, does not pose a safety risk to human health, is not nutritionally disadvantageous, and is not misleading to consumers. Commission Implementing Regulation (EU) 2017/2469 establishes administrative and scientific requirements for applications, specifying data formats, study protocols, and documentation standards. This implementing regulation requires applicants to conduct or compile studies following OECD guidelines and Good Laboratory Practice standards.

EFSA Assessment Process

Upon receiving a valid application, EFSA has nine months to adopt a scientific opinion on the novel food's safety. This timeline can be extended if EFSA requests additional information from the applicant, with the clock stopping during the period the applicant prepares responses. In practice, CBD applications have experienced multiple rounds of additional information requests, extending the process to 3-5 years. EFSA's assessment focuses on three primary safety questions: Does the novel food pose toxicological risks? Does it pose allergenicity risks? Does it have adverse nutritional effects? For CBD, the primary concern has centered on potential genotoxicity based on in vitro studies showing chromosomal aberrations at high concentrations. EFSA has required applicants to conduct additional in vivo studies to clarify whether these in vitro findings translate to actual genotoxic risk in living organisms.

Authorization Decision

Following a positive EFSA opinion, the European Commission drafts an implementing regulation authorizing the novel food and specifying conditions of use. This draft is submitted to the Standing Committee on Plants, Animals, Food and Feed, where member states vote. Authorization requires a qualified majority of member states supporting the measure. If no qualified majority emerges, the draft is referred to an appeal committee. If the appeal committee also fails to reach a qualified majority, the Commission may adopt the authorization independently. The authorization process creates significant political risk, as member states with domestic opposition to CBD could block authorization even after positive EFSA opinions. France's aggressive enforcement stance suggests it would likely oppose CBD authorization in Standing Committee votes, potentially creating a blocking minority.

Enforcement and Penalties

Member states retain primary responsibility for enforcing food safety law within their territories. Penalties for placing unauthorized novel foods on the market vary by jurisdiction but typically include product seizures, administrative fines, and potential criminal prosecution for repeat offenders. In France, penalties under the Consumer Code can reach €300,000 for legal entities and include imprisonment for individuals in cases of willful violation. The EU's Rapid Alert System for Food and Feed (RASFF) facilitates information sharing about non-compliant products, including unauthorized novel foods. CBD products have generated hundreds of RASFF notifications since 2019, triggering coordinated enforcement actions across multiple member states.

Interaction with Drug Control Law

The 1961 UN Single Convention on Narcotic Drugs and the EU's own drug control framework create additional complexity. While the European Court of Justice clarified in Case C-663/18 that CBD itself is not a narcotic, products must still comply with THC limits. Most member states require that CBD products contain less than 0.2% or 0.3% THC, though these limits lack harmonization across the EU. The interplay between food law and drug law creates enforcement challenges. A product might simultaneously violate novel food requirements (by containing unauthorized CBD) and drug control law (by exceeding THC limits), subjecting operators to multiple enforcement regimes.

State-by-State Breakdown

France

France has adopted the EU's most restrictive approach to CBD edibles. The May 2026 ban prohibits all CBD-containing foods, beverages, and dietary supplements regardless of CBD concentration or THC content. French authorities classify CBD edibles as unauthorized novel foods requiring immediate market removal. The ban does not affect CBD cosmetics, topical products, or hemp seed foods naturally containing trace cannabinoids. France permits cultivation of hemp varieties listed in the EU Common Catalogue with THC content below 0.3%, but extracted CBD cannot be added to food products. Enforcement is conducted by DGCCRF through inspections, product seizures, and administrative penalties reaching €300,000 for companies.

Germany

Germany takes a more nuanced enforcement approach, distinguishing between CBD products making therapeutic claims and those marketed as general foods. The Federal Office of Consumer Protection and Food Safety considers CBD extracts to be novel foods requiring authorization but has not implemented a blanket prohibition. German authorities focus enforcement on products exceeding 0.2% THC, making disease treatment claims, or targeting vulnerable populations such as children. Many CBD products remain available in German retail channels as of mid-2026, though operators face legal uncertainty. Several German states have issued guidance documents acknowledging the novel food issue while declining to mandate immediate market removal pending EFSA decisions.

Netherlands

The Netherlands Food and Consumer Product Safety Authority has adopted a risk-based enforcement priority system. The agency focuses resources on products with elevated THC levels, contamination issues, or misleading health claims rather than pursuing all CBD edibles as unauthorized novel foods. Dutch authorities have issued warning letters to companies making therapeutic claims but have not conducted widespread raids or seizures of compliant CBD products. The Netherlands permits hemp cultivation under EU rules and hosts several major CBD manufacturers serving European markets. This relatively permissive approach has made the Netherlands a hub for CBD commerce, though legal uncertainty persists.

Italy

Italy's enforcement landscape varies significantly by region, creating a fragmented market within a single member state. Northern regions including Lombardy and Veneto have conducted aggressive enforcement campaigns, raiding CBD shops and seizing products. Southern regions have generally adopted more lenient approaches. The Italian Ministry of Health issued guidance in 2020 stating that CBD extracts constitute novel foods, but national-level enforcement has been inconsistent. Italian courts have issued conflicting rulings on CBD legality, with some acquitting retailers based on the ECJ's Case C-663/18 ruling while others have upheld convictions for selling unauthorized novel foods. Italy permits hemp cultivation for fiber and seed production under the 2016 Hemp Law (Law 242/2016), but the law's application to CBD extraction remains contested.

Spain

Spain's enforcement approach mirrors Italy's regional variation. The Spanish Agency for Food Safety and Nutrition (AESAN) recognizes CBD extracts as novel foods but has not mandated nationwide removal. Catalonia has adopted a relatively permissive stance, with Barcelona hosting numerous CBD retail locations. Madrid and other central regions have conducted more aggressive enforcement. Spanish authorities require that CBD products contain less than 0.2% THC and prohibit therapeutic claims. Spain's hemp cultivation sector has grown substantially, with Catalonia and Andalusia hosting major production areas. The lack of harmonized national enforcement creates competitive distortions between regions.

Austria

Austria initially adopted a strict interpretation of the novel food framework, with authorities conducting raids and seizures in 2018-2019. Following the ECJ's 2020 ruling in Case C-663/18, Austrian enforcement moderated somewhat. The Austrian Agency for Health and Food Safety (AGES) maintains that CBD extracts require novel food authorization but has not implemented a comprehensive ban. Austrian authorities focus enforcement on products exceeding 0.3% THC or making medicinal claims. Austria permits hemp cultivation and hosts several CBD manufacturers, though the regulatory environment remains uncertain.

Belgium

Belgium's Federal Agency for the Safety of the Food Chain (FASFC) issued guidance in 2020 stating that CBD-containing foods require novel food authorization. Belgian authorities have conducted targeted enforcement actions but have not implemented systematic market removal. Belgium permits the sale of CBD products containing less than 0.2% THC and not making therapeutic claims, though the novel food requirement creates legal ambiguity. Belgian prosecutors have pursued some CBD retailers, but convictions have been inconsistent.

Switzerland

Switzerland, while not an EU member state, has developed its own CBD regulatory framework that influences the broader European market. Swiss law permits CBD products containing less than 1.0% THC—a significantly higher threshold than most EU jurisdictions. Switzerland does not apply the EU Novel Food Regulation, instead regulating CBD under its own food safety framework. The Swiss Federal Food Safety and Veterinary Office has authorized CBD as a food ingredient at specified concentrations. This permissive approach has made Switzerland a manufacturing hub for CBD products, some of which are exported to EU markets despite regulatory uncertainty. The divergence between Swiss and EU frameworks creates cross-border trade complications.

Market and Business Implications

The EU Novel Food Regulation has fundamentally restructured the European CBD market, redirecting capital toward cosmetic applications and creating a bifurcated industry. The European CBD market was valued at approximately €1.3 billion in 2025, down from a projected €1.7 billion had regulatory clarity emerged. The novel food uncertainty has suppressed market growth by an estimated 35-40% compared to pre-2019 trajectories. France's 2026 ban removes approximately €180 million in annual sales from the addressable market, with ripple effects across the supply chain.

Multi-State Operator Impact

Large cannabis companies with European ambitions have largely abandoned CBD food strategies in favor of cosmetic and wellness products not intended for ingestion. Curaleaf, which acquired European hemp company EMMAC in 2020, has pivoted its European operations toward topical products and away from edibles. Tilray Brands maintains European hemp cultivation operations but focuses on fiber, seed, and cosmetic applications rather than CBD food products. European-based MSOs face existential challenges. Companies that invested heavily in food-grade extraction facilities, product development, and retail distribution networks have seen valuations collapse. Several major European CBD brands have entered insolvency proceedings since 2023, unable to sustain operations amid regulatory uncertainty and enforcement actions.

Wholesale Market Dynamics

The wholesale CBD isolate market has experienced severe price compression. Bulk CBD isolate traded at €3,000-5,000 per kilogram in 2019-2020 but has fallen to €800-1,200 per kilogram as of mid-2026. This price collapse reflects oversupply as cultivation expanded faster than legal market access, combined with demand destruction from enforcement actions. Hemp farmers who invested in CBD-focused genetics and extraction infrastructure face negative margins, with many returning to traditional fiber and seed production. The cosmetic-grade CBD market has partially absorbed displaced demand, with wholesale prices for cosmetic-grade isolate maintaining a premium of 20-30% over food-grade material. This price differential reflects the regulatory clarity available for cosmetic applications under the EU Cosmetics Regulation (EC) No 1223/2009, which does not classify CBD as a novel ingredient requiring pre-market authorization.

Capital Markets and Investment

Venture capital and private equity investment in European CBD food companies has effectively ceased. Investors view the regulatory environment as prohibitively risky, with no clear timeline for resolution. The few funding rounds that have closed since 2023 have focused on companies with diversified revenue streams including cosmetics, pet products, or non-EU markets. Public market valuations for European hemp companies have declined 60-80% from 2020 peaks. Companies with significant CBD food exposure trade at distressed valuations, while those that successfully pivoted to cosmetics or other applications have fared better. The capital drought has forced consolidation, with stronger operators acquiring distressed competitors at steep discounts.

Supply Chain Reconfiguration

The regulatory uncertainty has triggered supply chain reconfiguration toward jurisdictions with clearer legal frameworks. Some European hemp processors have established operations in Switzerland to access its more permissive regulatory environment, then navigate complex export rules to reach EU consumers. Others have abandoned European markets entirely, redirecting production to North American or Asian markets with established CBD regulatory pathways. Contract manufacturers face particular challenges, as brand partners have canceled orders and terminated agreements due to regulatory risk. Extraction facilities built specifically for food-grade CBD production sit idle or have been repurposed for cosmetic applications, requiring costly equipment modifications and quality system updates.

Retail Sector Impact

The retail CBD sector has contracted sharply, with an estimated 40% of European CBD shops closing since 2022. Surviving retailers have diversified into hemp-derived products not subject to novel food requirements, including hemp seed foods, hemp fiber textiles, and CBD cosmetics. The France ban alone has forced closure of approximately 300 CBD retail locations, with former shop owners facing inventory write-offs and lease obligations. E-commerce platforms have implemented varying policies toward CBD products. Some platforms including Amazon prohibit CBD listings entirely, while others permit cosmetic CBD but not ingestible products. Payment processors have similarly restricted CBD transactions, with some banks and credit card networks categorizing CBD as high-risk regardless of product type.

What Experts Say

Scientific and legal experts have offered sharply divergent assessments of the EU's approach to CBD regulation, with food safety authorities emphasizing precaution while industry scientists argue the framework is disproportionate. According to the European Food Safety Authority, the primary safety concern regarding CBD centers on potential genotoxicity observed in some in vitro studies. EFSA officials have stated in public forums that the agency requires applicants to conclusively demonstrate that CBD does not pose genotoxic risks at proposed use levels before authorization can proceed. The agency maintains that this standard applies equally to all novel food applications and does not represent unique scrutiny of CBD. Dr. Ariane Leclercq, a toxicologist who has consulted on CBD novel food applications, said the genotoxicity concern stems from studies showing chromosomal aberrations in mammalian cells exposed to high CBD concentrations. She noted that subsequent in vivo studies have generally not replicated these findings, suggesting the in vitro results may not translate to actual human risk. According to Leclercq, the challenge for applicants is designing studies that definitively resolve EFSA's concerns while remaining economically feasible. The European Industrial Hemp Association has consistently argued that the novel food classification itself is inappropriate for hemp extracts. According to EIHA legal counsel, historical evidence demonstrates that hemp preparations containing CBD were consumed in various European countries before 1997, including hemp teas, tinctures, and traditional preparations. The association maintains that this consumption history should exempt CBD from novel food requirements or at least justify a streamlined authorization pathway. Professor Amedeo Reynaud, a food law specialist at the University of Parma, said the CBD situation highlights fundamental tensions in the EU novel food framework. According to Reynaud, the regulation was designed primarily for GMOs and synthetic ingredients, not botanical extracts with traditional use histories. He noted that the framework lacks mechanisms for efficiently processing applications for plant-derived substances that may have been consumed historically but lack comprehensive documentation. Industry analysts have characterized the regulatory environment as a case study in policy failure. According to Prohibition Partners, a cannabis industry research firm, the EU's approach has created the worst of all outcomes: consumers lack access to regulated products, legitimate businesses face insolvency, and illicit markets flourish. The firm's analysts note that unregulated CBD products remain widely available through online marketplaces and informal channels, undermining the novel food framework's consumer protection objectives. Consumer advocacy organizations have criticized both the regulatory uncertainty and enforcement inconsistency. According to the European Cannabis Industry Council, the lack of harmonized enforcement creates an unlevel playing field where companies in permissive jurisdictions gain competitive advantages over those in restrictive member states. The organization has called for EU-level coordination to ensure consistent application of food safety law across the single market. Some member state officials have privately expressed frustration with the prolonged authorization process. According to sources familiar with Standing Committee discussions, several member states believe EFSA's safety concerns could be addressed through conditional authorizations with post-market monitoring requirements, rather than indefinite delays pending perfect data. However, these member states have not publicly broken with the Commission's approach.

What's Next

The EU CBD regulatory situation faces several critical decision points in 2026-2027 that will determine whether the market achieves legal clarity or faces continued uncertainty. EFSA is expected to issue scientific opinions on at least three CBD novel food applications during the second half of 2026, according to the agency's published work program. These opinions will provide the first definitive scientific assessment of CBD's safety for food use under EU law. Positive opinions would enable the Commission to draft authorization regulations, while negative opinions would effectively close the EU market to CBD edibles indefinitely. Industry sources anticipate that EFSA will adopt a tiered approach, potentially approving CBD at low concentrations (such as 10-20 mg per day) while requiring additional data for higher intake levels. This outcome would provide limited market access while maintaining precautionary standards. However, such restricted authorizations might not be economically viable for companies that have invested in higher-concentration products. The European Commission faces political pressure to resolve the CBD question ahead of the 2027 European Parliament elections. Several member states have indicated that the prolonged uncertainty damages the EU's reputation for science-based regulation and creates unnecessary barriers to agricultural innovation. However, France's hardline stance complicates any Commission effort to facilitate CBD market access, as French opposition could block authorization votes in the Standing Committee. Legal challenges to member state enforcement actions continue to work through national court systems. Several cases are pending that could generate preliminary reference requests to the European Court of Justice, potentially producing additional ECJ guidance on CBD regulation. A ruling that member states cannot prohibit CBD products pending novel food authorization would fundamentally alter the enforcement landscape, though such an outcome appears unlikely given the ECJ's general deference to food safety precaution. The French ban specifically faces legal challenges from industry associations and affected companies. Trade groups have filed administrative appeals arguing that the blanket prohibition violates EU single market principles and exceeds France's enforcement authority. These challenges will likely take 18-24 months to resolve through French administrative courts, with potential appeals to the Conseil d'État and possible ECJ referral. The hemp cultivation sector faces critical decisions about 2027 planting intentions. Farmers must commit to genetics and acreage by early 2027 for the growing season, but regulatory uncertainty makes it impossible to assess whether CBD extraction will be viable. Industry analysts expect continued contraction in hemp cultivation dedicated to CBD production, with acreage shifting back toward fiber and seed applications. International developments may influence EU policy. The United States FDA is conducting its own CBD regulatory review, with potential guidance expected in 2026-2027. If the FDA establishes a clear regulatory pathway for CBD in food, this could create pressure on EU authorities to adopt comparable approaches or risk competitive disadvantage. Conversely, if the FDA maintains its current prohibition on CBD in food, this would validate the EU's precautionary stance. Switzerland's divergent approach creates ongoing tension. Swiss manufacturers continue to produce CBD products under Switzerland's permissive framework, with some products reaching EU consumers through gray-market channels. The EU may seek bilateral agreements with Switzerland to harmonize CBD regulation or may intensify border controls to prevent entry of non-compliant products. The cosmetic CBD market will likely continue expanding regardless of food regulatory outcomes. The EU Cosmetics Regulation provides clear legal authority for CBD in topical products, and this sector has absorbed significant capital and talent from the food market. By 2028, cosmetic applications may represent 60-70% of total European CBD sales, fundamentally reorienting the industry away from ingestible products.

Further Reading

• Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods - https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32015R2283
• European Commission Novel Food Catalogue - https://ec.europa.eu/food/safety/novel_food/catalogue_en
• European Court of Justice Case C-663/18 (BS and CA judgment) - https://curia.europa.eu/juris/document/document.jsf?docid=233925
• European Food Safety Authority Novel Foods Applications - https://www.efsa.europa.eu/en/applications/novel-foods
• European Industrial Hemp Association position papers - https://eiha.org/
• Commission Implementing Regulation (EU) 2017/2469 on novel food applications - https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32017R2469
• French DGCCRF guidance on CBD products - https://www.economie.gouv.fr/dgccrf
• German BVL novel food information - https://www.bvl.bund.de/EN/Home/homepage_node.html